Prognostic or predictive value of MGMT promoter methylation in gliomas depends on IDH1 mutation.
about
Advances in the treatment of newly diagnosed glioblastomaOligodendroglioma: pathology, molecular mechanisms and markersCase comparison and literature review of glioblastoma: A tale of two tumorsAdvances in diagnostic and treatment modalities for intracranial tumors.Exogenous IGFBP-2 promotes proliferation, invasion, and chemoresistance to temozolomide in glioma cells via the integrin β1-ERK pathwayAssessing CpG island methylator phenotype, 1p/19q codeletion, and MGMT promoter methylation from epigenome-wide data in the biomarker cohort of the NOA-04 trial.Prognostic and predictive biomarkers: tools in personalized oncology.The combination of IDH1 mutations and MGMT methylation status predicts survival in glioblastoma better than either IDH1 or MGMT alone.The impact of concurrent temozolomide with adjuvant radiation and IDH mutation status among patients with anaplastic astrocytoma.A new sensitive PCR assay for one-step detection of 12 IDH1/2 mutations in glioma.Personalized medicine for gliomasThe future of high-grade glioma: Where we are and where are we going.Somatostatin receptor subtype 2 in high-grade gliomas: PET/CT with (68)Ga-DOTA-peptides, correlation to prognostic markers, and implications for targeted radiotherapyEvolution of DNA repair defects during malignant progression of low-grade gliomas after temozolomide treatment.MGMT Promoter Methylation and BRAF V600E Mutations Are Helpful Markers to Discriminate Pleomorphic Xanthoastrocytoma from Giant Cell Glioblastoma.DNA Methylation and Somatic Mutations Converge on the Cell Cycle and Define Similar Evolutionary Histories in Brain TumorsPersonalized care in neuro-oncology coming of age: why we need MGMT and 1p/19q testing for malignant glioma patients in clinical practice.IDH mutation and MGMT promoter methylation in glioblastoma: results of a prospective registry.Radiological features combined with IDH1 status for predicting the survival outcome of glioblastoma patients.Radiation combined with temozolomide contraindicated for young adults diagnosed with anaplastic glioma.Neuro-oncology in 2013: improving outcome in newly diagnosed malignant glioma.MGMT testing--the challenges for biomarker-based glioma treatment.Towards developing biomarkers for glioblastoma multiforme: a proteomics view.Pharmacologic therapies for malignant glioma: a guide for clinicians.Epigenetic alterations in cancer and personalized cancer treatment.Long-term analysis of the NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with PCV or temozolomide.Chemotherapy in glioma.Anaplastic glioma: current treatment and management.Glioblastoma: pathology, molecular mechanisms and markers.Diagnostic, prognostic and predictive relevance of molecular markers in gliomas.Molecularly based management of gliomas in clinical practice.Emerging circulating biomarkers in glioblastoma: promises and challenges.Recent developments in predictive biomarkers of pediatric gliomaThe Diagnostic Use of Immunohistochemical Surrogates for Signature Molecular Genetic Alterations in Gliomas.Diagnostic and Therapeutic Biomarkers in Glioblastoma: Current Status and Future Perspectives.Advances in the molecular genetics of gliomas - implications for classification and therapy.Temozolomide chemotherapy versus radiotherapy in high-risk low-grade glioma (EORTC 22033-26033): a randomised, open-label, phase 3 intergroup study.Isocitrate Dehydrogenase (IDH)1/2 Mutations as Prognostic Markers in Patients With GlioblastomasMilestones of the last 10 years: CNS cancerDNA methylation in adult diffuse gliomas.
P2860
Q26773514-1A963B6F-53B0-42CF-8A47-2F911EFB24AEQ27002448-8ED16FD6-5A9A-402F-95FB-C65E7A333D67Q27014996-FA05CC32-3EF6-4CD0-8C17-F87D4FC48996Q30358150-9074D8FA-AFE1-4858-B04E-B90DF63CDA2DQ30402547-9A0CE57C-9DD8-4E88-99DD-D31B72D69C66Q30836702-B573E215-6C3F-4926-9995-2FC880D1C6F6Q33651583-E34F840E-F036-4877-8CBE-C46B262FDBF4Q34061985-2833B1E6-685F-492B-B227-88B42ABE92B5Q34498352-44A79D83-78FA-408E-BC0D-3E4FF7A66BAEQ34501052-074BBDF9-78E7-4567-BFFB-1FDC8EA17CCBQ35114080-C1B761DF-1F9F-416C-A38D-91A8419E5C68Q35114090-383A2B0E-C780-40AE-B609-6E11AD13B7A7Q35572487-E731836D-BF1B-4F13-BE61-43B428B242ABQ35787908-D302C919-E332-46DB-8AA5-61E31F576311Q36037961-807E4922-A3D6-40B3-AB69-3D86231114A0Q36069167-ECCD92D9-C6DA-4537-ACF0-B1C67E99737FQ36344709-3DC22340-871D-4A49-8147-C6B63032B1A7Q36562205-D20CEA7D-DDA1-4B13-91E3-842994BB7F46Q36705913-33DE03D3-9B86-4A40-9BD2-BB41E79E4E51Q37694886-A12DE667-7320-4A86-8059-17D4029234AFQ38178105-8904DA80-9C6D-4129-BBE6-2A97C6FBA2E9Q38218848-9F0F303E-D71D-4DF1-B317-2859E95CC1D6Q38239173-71EA01F4-D0CA-4AD5-8499-55265C767CD0Q38268897-138C156E-4333-4DDB-B5A4-DC4AB51F1FF5Q38319591-214D990D-E036-4D57-91B0-CD09C0551EFAQ38390616-016EBD33-EA7A-42E7-AF99-315D8F643C33Q38438439-F086ABA1-6921-4D10-AEAB-EFB027FE9165Q38456018-2A6580A4-233B-4404-8058-A6D5CB90BB4CQ38460865-5F26E4AB-2561-4291-9DD5-E8F0D2250947Q38461565-EC2010E3-FF62-4413-8187-0EC719B830AAQ38551010-49FA328E-74A3-4BEE-8522-A2E5D9815AC9Q38591062-84762C43-5932-4942-8415-45FCEA6FC029Q38660101-FA294D18-9F70-4AE9-962A-209B8573BA1CQ38670567-0694434E-C948-40F4-8619-66BA2CBF6201Q38743138-E7C9AFF7-0F94-4AC2-878C-D3EBBEF27B93Q38777058-6DF552A7-0B8D-4561-822F-7D4AAE0F93E5Q38816272-909C898D-F5A5-4C76-AAF8-C9371162001AQ38843549-AA3699E8-8D60-43C6-8745-44C9B71302AAQ38861548-85484B2B-D437-4404-B0CD-8444118A0B94Q38861997-64469F60-65C3-4116-9DBC-EF40E50F97AD
P2860
Prognostic or predictive value of MGMT promoter methylation in gliomas depends on IDH1 mutation.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
2013年學術文章
@zh-hant
name
Prognostic or predictive value ...... omas depends on IDH1 mutation.
@en
type
label
Prognostic or predictive value ...... omas depends on IDH1 mutation.
@en
prefLabel
Prognostic or predictive value ...... omas depends on IDH1 mutation.
@en
P2093
P50
P1433
P1476
Prognostic or predictive value ...... omas depends on IDH1 mutation.
@en
P2093
Alissa Schilling
Benedikt Wiestler
Bettina Hentschel
Christoph Meisner
Dorothee Gramatzki
Gabriele Schackert
Manfred Westphal
Markus Loeffler
Markus Weiler
Matthias Simon
P304
P356
10.1212/WNL.0B013E3182A95680
P407
P50
P577
2013-09-25T00:00:00Z